Adma Biologics (ADMA) EBIAT: 2011-2025
Historic EBIAT for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $36.4 million.
- Adma Biologics' EBIAT rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 207.41%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
- Per Adma Biologics' latest filing, its EBIAT stood at $36.4 million for Q3 2025, which was up 6.46% from $34.2 million recorded in Q2 2025.
- Over the past 5 years, Adma Biologics' EBIAT peaked at $111.9 million during Q4 2024, and registered a low of -$25.0 million during Q1 2022.
- Over the past 3 years, Adma Biologics' median EBIAT value was $26.9 million (recorded in 2025), while the average stood at $24.3 million.
- As far as peak fluctuations go, Adma Biologics' EBIAT slumped by 44.26% in 2023, and later soared by 1,299.96% in 2024.
- Adma Biologics' EBIAT (Quarterly) stood at -$16.6 million in 2021, then increased by 26.54% to -$12.2 million in 2022, then crashed by 44.26% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then grew by 1.45% to $36.4 million in 2025.
- Its EBIAT was $36.4 million in Q3 2025, compared to $34.2 million in Q2 2025 and $26.9 million in Q1 2025.